<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03143751</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0474</org_study_id>
    <nct_id>NCT03143751</nct_id>
  </id_info>
  <brief_title>Continuous Hyperosomolar Therapy for Traumatic Brain-injured Patients</brief_title>
  <acronym>COBI</acronym>
  <official_title>Continuous Hyperosomolar Therapy for Traumatic Brain-injured Patients Study Protocol for a Multicenter Randomized Open-label Trial With Blinded Adjudication of Primary Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traumatic brain injury (TBI) is a major cause of death and severe prolonged disability.&#xD;
      Intracranial hypertension (ICH) is a critical risk factor of bad outcomes after TBI.&#xD;
      Continuous infusion of hyperosmolar therapy has been proposed for the prevention or the&#xD;
      treatment of ICH. Whether an early administration of continuous hyperosmolar therapy improves&#xD;
      long term outcomes is uncertain. The aim of the current study is to assess the efficiency and&#xD;
      the safety of continuous hyperosmolar therapy in TBI patients.&#xD;
&#xD;
      The COBI trial is the first randomized controlled trial powered to investigate whether&#xD;
      continuous hyperosmolar therapy in TBI patients improve long term recovery.&#xD;
&#xD;
      Hypothesis&#xD;
&#xD;
      Patients treated with early continuous hyperosmolar therapy have reduced morbidity and&#xD;
      mortality rates compared to those receiving standard care alone after traumatic brain injury.&#xD;
&#xD;
      Research Questions&#xD;
&#xD;
        1. Does early continuous hyperosmolar therapy reduce morbidity and mortality rates at 3 and&#xD;
           6 months after TBI assessed by the GOSE questionnaire?&#xD;
&#xD;
        2. Does early continuous hyperosmolar therapy prevent intracranial hypertension?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Traumatic brain injury (TBI) is a major cause of death and severe prolonged&#xD;
      disability. Intracranial hypertension (ICH) is a critical risk factor of bad outcomes after&#xD;
      TBI.&#xD;
&#xD;
      Continuous infusion of hyperosmolar therapy has been proposed for the prevention or the&#xD;
      treatment of ICH. Whether an early administration of continuous hyperosmolar therapy improves&#xD;
      long term outcomes is uncertain. The aim of the current study is to assess the efficiency and&#xD;
      the safety of continuous hyperosmolar therapy in TBI patients.&#xD;
&#xD;
      Methods The COBI (Continuous hyperosmolar therapy in traumatic brain-injured patients) trial&#xD;
      is a multicenter, randomized, controlled, open-label, two-arms study with blinded&#xD;
      adjudication of primary outcome. Three hundred and seventy patients hospitalized in Intensive&#xD;
      Care Unit with a traumatic brain injury (Glasgow Coma Scale â‰¤ 12 and abnormal brain CT-scan)&#xD;
      are randomized in the first 24 hours following trauma to standard care or continuous&#xD;
      hyperosmolar therapy (NaCl 20%) plus standard care. Continuous hyperosmolar therapy is&#xD;
      maintained for at least 48 hours in the treatment group and continued for as long as is&#xD;
      necessary to prevent intracranial hypertension. The primary outcome is the score on the&#xD;
      Extended Glasgow Outcome Scale (GOS-E) at 6 months. The treatment effect is estimated with&#xD;
      ordinal logistic regression adjusted for pre-specified prognostic factors and expressed as a&#xD;
      common odds ratio.&#xD;
&#xD;
      Discussion The COBI trial is the first randomized controlled trial powered to investigate&#xD;
      whether continuous hyperosmolar therapy in TBI patients improve long term recovery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2017</start_date>
  <completion_date type="Actual">March 5, 2020</completion_date>
  <primary_completion_date type="Actual">March 5, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Masking: Open label , Masked Roles: Subject and Outcomes assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Score on the Extended Glasgow Outcome Scale (GOS-E) at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>The GOS-E is a scale measuring the neurological recovery after traumatic brain injuries</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate in ICU</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate in ICU</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GOS-E</measure>
    <time_frame>3 months</time_frame>
    <description>The GOS-E is a scale measuring the neurological recovery after traumatic brain injuries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional independence measure : ADL (Activities of Daily Living) of Katz</measure>
    <time_frame>3 months</time_frame>
    <description>Scale measuring the autonomy of patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>functional independence measure : ADL (Activities of Daily Living) of Katz</measure>
    <time_frame>6 months</time_frame>
    <description>Scale measuring the autonomy of patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36</measure>
    <time_frame>3 months</time_frame>
    <description>Scale measuring the quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36</measure>
    <time_frame>6 months</time_frame>
    <description>Scale measuring the quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with anterograde amnesia</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with anterograde amnesia</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial pressure control</measure>
    <time_frame>7 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood level of sodium</measure>
    <time_frame>7 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood osmolality</measure>
    <time_frame>7 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of thrombo-embolic events</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute kidney injury</measure>
    <time_frame>28 days</time_frame>
    <description>KDIGO 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of centropontine myelinolysis</measure>
    <time_frame>28 days</time_frame>
    <description>Diagnosis on MRI realized in case of clinical suspicion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood level of chlore</measure>
    <time_frame>7 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood level of potassium</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood level of pH (Hydrogen Potention)</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>brain oxygenation (PtiO2)</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood level of creatinine</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diuresis</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ancillary study: questionnaire HADS (Hospital Anxiety and Depression Scale) in patient's relative</measure>
    <time_frame>6 months</time_frame>
    <description>Scale measuring the quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Moderate to Severe Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Continuous hyperosmolar therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard cares plus continuous hyperosmolar therapy (NaCl20%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard cares alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl20% (Continuous hyperosmolar therapy)</intervention_name>
    <description>Early intravenous administration (&lt;24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)&#xD;
1-hour bolus (15 g if Na+ &lt; 145 mmol/L; 7.5 g if 145 &lt; Na+ &lt; 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+&lt; 150 mmol/L, reduced to 0.5 g/L if 150 &lt; Na+ &lt; 155 mmol/L, Discontinuation when 155 mmol/L&lt;Na+</description>
    <arm_group_label>Continuous hyperosmolar therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-80 years old&#xD;
&#xD;
          -  Moderate to severe traumatic brain injury defined as the association of a Coma Glasgow&#xD;
             Scale â‰¤ 12 together with a traumatic abnormal brain CT-scan&#xD;
&#xD;
          -  Time to inclusion inferior to 24 hours&#xD;
&#xD;
          -  Informed consent (or emergency procedure)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  dependence for daily activity&#xD;
&#xD;
          -  Coma Glasgow Scale of 3 and fixed dilated pupils&#xD;
&#xD;
          -  associated cervical spine injury&#xD;
&#xD;
          -  imminent death and do-not-resuscitate orders&#xD;
&#xD;
          -  pregnancy.&#xD;
&#xD;
          -  Major not legally responsible&#xD;
&#xD;
          -  Oedemato-ascitic decompensation of hepatic cirrhosis&#xD;
&#xD;
          -  State of hydro-sodium retention secondary to heart failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Huet, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Brest</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lasocki Sigismond, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Angers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Geerraerts, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francis Remerand, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Tours</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe Seguin, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claire Dahyot, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Poitiers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre FranÃ§ois Perrigault, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Denis Moyer, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Beaujon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tarek SHARSHAR, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP Saint-Anne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brest Hopital La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92118</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sainte-Anne</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes-Hopital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse HÃ´pital Pierre-Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

